Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
TOPOTECAN HYDROCHLORIDE EQUIVALENT TO TOPOTECAN
Fresenius Kabi Oncology Plc
L01XX17
TOPOTECAN HYDROCHLORIDE EQUIVALENT TO TOPOTECAN
1 Mg/Ml
Concentrate for Soln for Inf
Product subject to prescription which may not be renewed (A)
Other antineoplastic agents
Authorised
2013-09-20
[ V inod Pal ] D:\FK-DA TA\Europe\T opotecan R TU\UK+IRL\T opotecan R TU Pack Insert - Bordon - UK+IRL.indd Size: 200 x 380 mm XXXXXX V001 XXXXXXXXXX TOPOTECAN RTU PACK INSERT - BORDON - UK+IRL Ver. 12 Times New Roman 9 pt. Last modified : 31 August 2013 2:26 PM Black THE FOLLOWING INFORMATION IS INTENDED FOR HEALTHCAR E PR OFESSIONALS ONLY: GENE RAL PR EC AUTIONS The norm al procedures for proper handli ng and dispos al of anticancer m edicinal products sho uld be adopted : - Staf f should be trained to dilute the m edicin al prod uct. - Pregnant staf f should be ex cluded from working with this medicinal product. - Staf f handling this m edicinal prod uct du ring dilution should wear protective clothing includi ng mask, goggles and gloves. - All item s for ad m inistration or cleaning, inclu ding gl oves, should be placed in hi gh-risk, waste disposal bags for hig h- temperature incineration. - Accidental co ntact with the skin or ey es should be treated immediately with copi ous am ounts of water . INSTRUCTIONS FOR DILUTION The concentrate is clear yellow to yellow green in colour and contains 1 m g per m l of topotecan. Further dilution of the appropriate volum e of the concentrate with either sodi um chloride 9 m g/ ml (0.9% ) solution fo r injection or glucose 50 m g/ m l (5%) solution for inj ection to reach a final topotecan concentration of between 25 and 50 m icrog ram /m l in the solution for in fusion. The diluted solution should be clear , colourless to light yellow colour , free from visible particles. STORAGE OF TH E DILUTED SOLUTION Chemical and physical in-use stability has been demonstrated PACKAGE LEAFLET: INFORMATION FOR THE USER TOPOTECA Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Topotecan 1 mg/ml Concentrate for Solution for Infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of concentrate contains 1 mg topotecan (as hydrochloride). One vial of 1 ml of concentrate contains 1 mg topotecan (as hydrochloride). One vial of 4 ml of concentrate contains 4 mg topotecan (as hydrochloride). For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Concentrate for solution for infusion. A clear yellow to yellow green colour solution, free from visible particles. pH = 2.0-2.6. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Topotecan monotherapy is indicated for the treatment of: patients with metastatic carcinoma of the ovary after failure of first line or subsequent therapy. patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate (see section 5.1). Topotecan in combination with cisplatin is indicated for patients with carcinoma of the cervix recurrent after radiotherapy and for patients with Stage IVB disease. Patients with prior exposure to cisplatin require a sustained treatment free interval to justify treatment with the combination (see section 5.1). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Method of administration The use of topotecan should be confined to units specialised in the administration of cytotoxic chemotherapy and should only be administered under the supervision of a physician experienced in the use of chemotherapy (see section 6.6). Topotecan must be further diluted before use (see section 6.6). The diluted solution should be clear, colourless to light yellow colour, free from visible particles. Posology When used in combination with cisplatin, the full prescribing information Read the complete document